Both the House and Senate overwhelmingly passed the
21st Century Cures Act to ensure $4.8 billion in new funding for biomedical research. President Obama signed the bill into law last week. $1.8 billion has been designated for the
Cancer Moonshot program, to be allocated over seven years, with the balance earmarked for other precision medicine initiatives. ACGT participated in the
Rally for Medical Research that pressed for this major funding legislation.
Learn more.
Show Your Support This Holiday Season
Please make your year-end gift today and support breakthrough cancer treatments. ACGT is the only philanthropic organization in the country dedicated exclusively to cell and gene therapies for cancer.
Support innovative, life-saving research.
Most Disruptive Innovation of the Year
BioPharma Dive, a media website devoted to biotech
and pharmaceutical news, bestowed its annual Dive awards last week. Their "Most Disruptive Innovation of the Year" award went to
CAR-T therapy for its potential as a new drug class to fight cancer.
CAR-T, also explained recently in
ACGT's blog on new frontiers in cancer therapies, has been particularly successful in human trials with leukemia and lymphomas.
See the full list of Dive awards.